Document:

Exhibit 4.5

 

CIPHERGEN
BIOSYSTEMS, INC.

 

SECOND
AMENDMENT TO RIGHTS AGREEMENT

 

THIS SECOND
AMENDMENT TO RIGHTS AGREEMENT (this “Amendment”) is made as of September 30, 2005 between CIPHERGEN BIOSYSTEMS, INC., a Delaware company (the “Company”),
and WELLS FARGO BANK, N.A. (the “Rights Agent”).

 

WHEREAS, the Company and Continental Stock Transfer &
Trust Company entered into a Preferred Shares Rights Agreement, dated as of March 20,
2002 (the “Rights Agreement”) (capitalized terms used in this Amendment
but not defined herein shall have the meaning assigned to them in the Rights
Agreement); and

 

WHEREAS, the Rights Agent became party to the Rights
Agreement upon their appointment as the Company’s transfer agent; and

 

WHEREAS, the Company and the Rights Agent desire to
amend the Rights Agreement as provided below; and

 

WHEREAS, the Company and the Rights Agent have agreed
that this Amendment will replace and supersede the previous amendment to the
Rights Agreement dated as of July 22, 2005 between the Company and the
Rights Agent.

 

NOW,
THEREFORE, in
consideration of the foregoing premises and the mutual covenants and conditions
set forth below, and for other good and valuable consideration, the receipt of
which is hereby acknowledged, the parties to this Amendment to the Rights
Agreement hereby agree as follows:

 

AMENDMENT

 

1.             Amendment
of the Rights Agreement.

 

1.1           Section 1(a) of
the Rights Agreement is hereby amended by inserting the following sentence
immediately after the last sentence thereof:

 

“Notwithstanding the foregoing, (x) none of Quest
Diagnostics Incorporated (“Quest Diagnostics”), nor any of its Affiliates,
shall be deemed an Acquiring Person and neither a Shares Acquisition Date nor a
Distribution Date shall be deemed to occur and the Rights will not separate
from Company Common Shares, in each case, solely by reason of the execution,
delivery, performance or consummation of the transactions contemplated under
the Stock Purchase Agreement and the Warrant (or the exercise of the Warrant)
each dated as of July 22, 2005, between the Company and Quest Diagnostics
(including any amendment or supplement thereto); (y) Quest Diagnostics shall
not be treated as an Associate or Affiliate of GlaxoSmithKline plc (“GlaxoSmithKline”)
or any of its Subsidiaries and none of GlaxoSmithKline or any of its
Subsidiaries shall be treated as an Affiliate of Quest Diagnostics at any time
that GlaxoSmithKline and its Subsidiaries together beneficially own less than
29.5% of the outstanding common stock or any other equity security of Quest
Diagnostics; and (z) Quest Diagnostics shall not be treated as an Affiliate of
any person and no person shall be treated

 

 

as an Associate or Affiliate of Quest Diagnostics at
any time that Quest Diagnostics and its Subsidiaries together beneficially own
less than 20% of the outstanding common stock of such person.”

 

2.             No
Other Amendment.  Except as modified
by this Amendment, the Rights Agreement shall remain in full force and effect
without any modification.  This Amendment
shall replace and supersede the Amendment to the Rights Agreement made as of July 22,
2005.  By executing this Amendment below,
the Company certifies that this Amendment has been executed and delivered in
compliance with the terms of Section 27 of the Rights Agreement.  This Amendment shall be deemed an amendment
to the Rights Agreement and shall become effective when executed and delivered
by the Company and the Rights Agent as provided under Section 27 of the
Rights Agreement.  This Amendment shall
be irrevocable and Quest Diagnostics, Inc. shall be an express third party
beneficiary hereof.

 

3.             Effect
of Amendment.  This Amendment shall
be deemed to be in force and effect immediately prior to the execution of the
Stock Purchase Agreement.  Except as and
to the extent expressly modified by this Amendment, the Rights Agreement and
the exhibits thereto, shall remain in full force and effect in all
respects.  In the event of a conflict or
inconsistency between this Amendment and the Rights Agreement and the exhibits
thereto, the provisions of this Amendment shall govern.

 

4.             Counterparts.  This Amendment may be executed in several
counterparts, each of which shall constitute an original and all of which, when
taken together, shall constitute one agreement.

 

5.             Miscellaneous.  This Amendment shall be deemed to be a
contract made under the laws of the state of Delaware and for all purposes
shall be governed by and construed in accordance with the laws of such state
applicable to contracts to be made and performed entirely within such
state.  If any term or other provision of
this Amendment is determined to be invalid, illegal or incapable of being
enforced by any rule of law or public policy, all other terms and
provisions of this Amendment shall nonetheless remain in full force and effect
and upon such determination that any term or other provision is invalid,
illegal or incapable of being enforced, this Amendment and such term or other
provision shall be deemed to have been amended so as to effect the original
intent of the parties as closely as possible in an acceptable manner to the
Board of Directors of the Company.

 

[Remainder of Page Left Blank
Intentionally]

 

 

The parties hereto have caused this Amendment to be
executed and delivered as of the day and year first written above.

 

	
  WELLS FARGO BANK, N.A.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /S/ JENNIFER LENO

  	
   

  
	
   

  	
   

  
	
  Name:

  	
  Jennifer Leno

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Assistant Vice President

  	
   

  
	
   

  	
   

  
	
  CIPHERGEN BIOSYSTEMS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /S/ MATTHEW J. HOGAN

  	
   

  
	
   

  	
   

  
	
  Name:

  	
  Matthew J. Hogan

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  CFO

  	
   

  
					

 

[SIGNATURE PAGE TO AMENDMENT TO
THE RIGHTS AGREEMENT]Exhibit 10.1

 

FIRST
AMENDMENT AND CONSENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT

 

THIS FIRST
AMENDMENT AND CONSENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT, dated as
of September 29, 2005 (this “Amendment”), to the Third Amended and
Restated Credit Agreement, dated as of June 30, 2005 (as amended,
supplemented or otherwise modified from time to time, the “Credit Agreement”),
by and among General Electric Capital Corporation, as Agent (in such capacity, “Agent”),
Inverness Medical Innovations, Inc. (“Innovations”), Wampole
Laboratories, LLC and Inverness Medical (UK) Holdings Limited, as borrowers (“Borrowers”),
the other Credit Parties signatory thereto, Merrill Lynch Capital, a division
of Merrill Lynch Business Financial Services Inc., as documentation agent,
co-syndication agent and lender, UBS Securities LLC, as co-syndication agent,
and the lenders signatory thereto from time to time (collectively, the “Lenders”).

 

W  I
T  N  E  S  S  E  T  H

 

WHEREAS,
Borrowers have notified Agent that Innovations desires to acquire (the “BioStar
Stock Purchase”) one hundred percent (100%) of the issued and outstanding
stock of Thermo BioStar, Inc., a Delaware corporation (“BioStar”),
for consideration (the “BioStar Closing Date Consideration”) of $52,500,000
in cash;

 

WHEREAS, in
addition to the BioStar Closing Date Consideration, under Section 2.2(b)(iv) of
that certain Stock Purchase Agreement by and between Innovations, Thermo
Electron Corporation and Thermo BioAnalysis Corporation, dated as of September 16,
2005 (the “BioStar Stock Purchase Agreement”), Innovations may be
required to make additional payments in respect of working capital (the “BioStar
Working Capital Payment”);

 

WHEREAS, the BioStar
Stock Purchase is not a Permitted Acquisition and therefore is prohibited under
Section 6.1 of the Credit Agreement;

 

WHEREAS,
Borrowers have requested that Agent and Requisite Lenders consent to the BioStar
Stock Purchase on the terms and subject to the conditions set forth herein;

 

WHEREAS,
Borrowers have notified Agent that Inverness Medical Switzerland GmbH (“Swissco”),
through a newly acquired wholly-owned subsidiary (“IDT Acquisition”), desires
to acquire (the “IDT Stock Purchase”) one hundred percent (100%) of the
issued and outstanding stock of Innogenetics Diagnostica y Terapeutica S.A.U.,
a Spanish limited liability company (“Inverness Iberica”), for
consideration (the “IDT Closing Date Consideration”) of up to €10,010,000;

 

WHEREAS, in
addition to the IDT Closing Date Consideration, under the terms of that Share
Sale and Purchase Agreement between Innogenetics NV and Swissco, dated as of September 29,
2005 (the “IDT Stock Purchase Agreement”), IDT Acquisition, as assignee
of Swissco under the IDT Stock Purchase Agreement, may be required to pay the
Purchase Price Adjustment (as defined in the IDT Stock Purchase Agreement);

 

1

 

WHEREAS, the IDT
Stock Purchase is not a Permitted Acquisition and therefore is prohibited under
Section 6.1 of the Credit Agreement;

 

WHEREAS,
Borrowers have requested that Agent and Requisite Lenders consent to the IDT
Stock Purchase on the terms and subject to the conditions set forth herein; and

 

WHEREAS, Agent
and Requisite Lenders have agreed to amend the Credit Agreement in the manner,
and on the terms and conditions, provided for herein.

 

NOW THEREFORE,
in consideration of the premises and for other good and valuable consideration,
the receipt, adequacy and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:

 

1.             Definitions.  Capitalized terms not otherwise defined
herein shall have the meanings ascribed to them in the Credit Agreement.

 

2.             Amendments
to Credit Agreement.

 

(a)           Clause
(c) of Section 6.2 of the Credit Agreement is hereby
amended as of the date the IDT Stock Purchase is consummated pursuant to the
terms of the IDT Stock Purchase Agreement (such date, the “IDT Acquisition
Effective Date”) (which date shall in no event be prior to the Effective
Date (as defined below)) by deleting such clause in its entirety and inserting
the following in lieu thereof:

 

“(c) the Credit Parties may make investments and
loans to Restricted Credit Parties, provided  that the aggregate
amount of such investments and loans to such Restricted Credit Parties permitted
by this clause (c) shall not exceed $3,000,000 (or the Equivalent
Amount thereof) at any time

 

(b)           Clause
(h) of Section 6.2 of the Credit Agreement is hereby
amended as of the IDT Acquisition Effective Date (which date shall in no event
be prior to the Effective Date) by deleting such clause in its entirety and
inserting the following in lieu thereof:

 

“(h) the
Credit Parties may make additional investments and loans not otherwise
permitted by this Section 6.2, provided  that the
aggregate amount of such investments and loans permitted by this clause (h) shall
not exceed $2,000,000 (or the Equivalent Amount thereof) at any time;”

 

(c)           Section 6.2
of the Credit Agreement is hereby amended as of the IDT Acquisition Effective
Date (which date shall in no event be prior to the Effective Date) by inserting
the following at the end of such section:

 

“and (i) the
Credit Parties may make investments in or loans to IDT Acquisition in an amount
necessary to permit IDT Acquisition to make payments required under that
certain Share Sale and Purchase Agreement between Innogenetics NV and Swissco
in connection with the purchase by IDT Acquisition, as assignee of Swissco
under such agreement, of Inverness Iberica.”

 

2

 

(d)           Clause
(ix) and clause (x) of Section 6.3(a) of the
Credit Agreement are hereby amended as of the IDT Acquisition Effective Date
(which date shall in no event be prior to the Effective Date) by deleting such
clauses in their entirety and inserting the following in lieu thereof:

 

“(ix) unsecured
Indebtedness incurred by Inverness Iberica in the ordinary course of business
and consistent with past practice to third party lending institutions in Spain
in connection with guaranties issued by such lending institutions to Spanish
health governmental entities; provided  that such guaranties are set
forth on Disclosure Schedule (6.3) (as updated pursuant to the
First Amendment and Consent to this Agreement) or are issued solely in
connection with Inverness Iberica’s participation in a public bidding process
to secure contracts with such Spanish health governmental entities or are
required pursuant to contracts entered into by Inverness Iberica with any such
Spanish health governmental entity to secure the performance of Inverness
Iberica under such contracts; (x) unsecured Indebtedness consistent with past
practice incurred by Inverness Iberica in connection with factoring arrangements
entered into with a third party factoring institutions; provided  that
such factoring arrangements do not relate to more than 50% of the Accounts of
Inverness Iberica at any time;”

 

(e)           Clause
(viii)(E) of Section 6.3(a) of the Credit Agreement is
hereby amended as of the IDT Acquisition Effective Date (which date shall in no
event be prior to the Effective Date) by deleting such clause in its entirety
and inserting the following in lieu thereof:

 

“(E) the
Restricted Credit Parties shall not be permitted to incur any Indebtedness to
any Credit Party if such Credit Party is not permitted to advance such
Indebtedness under Section 6.2(c) or Section 6.2(h),
or, in the case of incurrence of Indebtedness by IDT Acquisition only, Section 6.2(i),”

 

(f)            The
first sentence of clause (a) of Section 6.4 of the
Credit Agreement is hereby amended as of the IDT Acquisition Effective Date
(which date shall in no event be prior to the Effective Date) by deleting such
clause in its entirety and inserting the following in lieu thereof:

 

“(a)         Except as set forth on Disclosure Schedule (6.4)
and except as otherwise expressly permitted in this Section 6, with
respect to (i) Restricted Credit Parties (other than Orgenics Holding,
Inverness Iberica and IDT Acquisition), no Credit Party shall enter into or be
a party to any transaction with any Restricted Credit Party, except in the
ordinary course of business and consistent with past practices; and (ii) Affiliates,
no Credit Party shall enter into or be a party to any transaction with any
Affiliate of such Credit Party (other than any Affiliate which is a Credit Party
(other than Orgenics Holdings, Inverness Iberica and IDT Acquisition)) except
in the ordinary course of business and pursuant to the reasonable requirements
of such Credit Party’s business and upon fair and reasonable terms that are no
less favorable to such Credit Party than would be obtained in a

 

3

 

comparable arm’s
length transaction with a Person not an Affiliate of such Credit Party.”

 

(g)           The
first sentence of Section 6.8 of the Credit Agreement is hereby
amended as of the IDT Acquisition Effective Date (which date shall in no event
be prior to the Effective Date) by (i) deleting the word “and” at the end
of clause (d) thereof and (ii) inserting the following at the end of
such sentence:

 

“; and (f) the sale of Accounts by Inverness
Iberica consistent with past practice in connection with factoring arrangements
entered into with a third party factoring institutions; provided  that
such factoring arrangements do not relate to more than 50% of the Accounts of
Inverness Iberica at any time;

 

(h)           Annex
A of the Credit Agreement is hereby amended as of the date the BioStar
Stock Purchase is consummated pursuant to the terms of the BioStar Stock
Purchase Agreement (such date, the “BioStar Acquisition Effective Date”)
(which date shall in no event be prior to the Effective Date) by deleting the
definitions of “Commitments” and “US Revolving Loan Commitment” and inserting
the following in lieu thereof:

 

‘“Commitments”
means (a) as to any Lender, the aggregate of such Lender’s US Revolving
Loan Commitment (including without duplication the Swing Line Lender’s US Swing
Line Commitment as a subset of its US Revolving Loan Commitment), European
Revolving Loan Commitment (including without duplication the Swing Line Lender’s
European Swing Line Commitment as a subset of its European Revolving Loan
Commitment), US Term Loan Commitment and European Term Loan Commitment as set
forth on Annex I to this Agreement or in the most recent Assignment
Agreement executed by such Lender, and (b) as to all Lenders, the
aggregate of all Lenders’ US Revolving Loan Commitments (including without
duplication the Swing Line Lender’s US Swing Line Commitment as a subset of its
US Revolving Loan Commitment), European Revolving Loan Commitments (including
without duplication the Swing Line Lender’s European Swing Line Commitment as a
subset of its European Revolving Loan Commitment), US Term Loan Commitments and
European Term Loan Commitments, which aggregate commitment shall be ONE HUNDRED
MILLION DOLLARS ($100,000,000) as of the BioStar Acquisition Effective Date, as
to each of clauses (a) and (b), as such Commitments may
be reduced, amortized or adjusted from time to time in accordance with the
Agreement.”

 

“US
Revolving Loan Commitment” means (a) as to any Lender, the aggregate
commitment of such Lender to make US Revolving Credit Advances as set forth on Annex I
to this Agreement or in the most recent Assignment Agreement executed by such
Lender and (b) as to all Lenders, the aggregate commitment of all Lenders
to make US Revolving Credit Advances, which aggregate commitment shall be SIXTY
MILLION DOLLARS ($60,000,000) as of the BioStar Acquisition Effective Date, as
such amount may be adjusted, if at all, from time to time in accordance with
this Agreement.”

 

4

 

(i)            Annex
A of the Credit Agreement is hereby amended as of the IDT Acquisition
Effective Date (which date shall in no event be prior to the Effective Date) by
deleting the definition of “Restricted Credit Parties” and inserting the
following in lieu thereof:

 

‘“Restricted Credit Parties” means,
collectively (a) Inverness Japan, (b) Inverness Medical France SAS, (c) Inverness
Iberica, (d) IDT Acquisition, and (e) Orgenics International
Holdings, BV.”

 

(j)            Annex
A of the Credit Agreement is hereby amended as of the BioStar Acquisition Effective
Date (which date shall in no event be prior to the Effective Date) by inserting
the following new definition in alphabetical order therein:

 

‘“BioStar
Acquisition Effective Date” the date on which the purchase by Innovations
of 100% of the outstanding equity of Thermo BioStar, Inc. is consummated
subject to the terms and conditions set forth in the First Amendment and
Consent to Third Amended and Restated Credit Agreement, dated as of September 29,
2005, by and among the Credit Parties, Agent and the other Lenders signatory
thereto.”

 

(k)           Annex
A of the Credit Agreement is hereby amended as of the IDT Acquisition
Effective Date (which date shall in no event be prior to the Effective Date) by
inserting the following new definitions in alphabetical order therein:

 

‘“IDT
Acquisition” means Boswell Investments SAU.”

 

‘“Inverness
Iberica” means Innogenetics Diagnostica y Terapeutica S.A.U., a Spanish
limited liability company.”

 

(l)            Annex
I of the Credit Agreement is hereby amended as of the BioStar Acquisition Effective
Date (which date shall in no event be prior to the Effective Date) by deleting
it in its entirety and replacing it with Annex I attached hereto.

 

3.             BioStar
Consent.  As of the Effective Date,
Agent and Requisite Lenders (a) consent to the consummation of the BioStar
Stock Purchase in accordance with the BioStar Stock Purchase Agreement and
related documentation previously provided to and approved by Agent (the “Draft
BioStar Stock Purchase Documents”), and (b) agree that the BioStar
Stock Purchase on or before October 31, 2005, in accordance with the Draft
BioStar Stock Purchase Documents, shall not constitute a breach of the Credit
Agreement or the other Loan Documents, provided, however, that
the Credit Parties do not expend any cash or other consideration in connection
with the BioStar Stock Purchase other than (x) for costs and expenses not to
exceed $1,000,000 in the aggregate, (y) the BioStar Closing Date Consideration
and (z) the BioStar Working Capital Payment in an amount not to exceed $599,999.  Agent and Requisite Lenders further agree
that, following the BioStar Acquisition Effective Date, BioStar may change its
name; provided  that immediately following such change, Borrowers
shall provide Agent with a full, complete and correct certificate of
incorporation of BioStar reflecting such change.

 

4.             Agreement
by Borrowers and Other Credit Parties Regarding BioStar Stock Purchase.  The Borrowers and each of the other Credit
Parties hereby acknowledge and

 

5

 

agree that, on or prior to the BioStar Acquisition
Effective Date (or on or prior to such other date as may be expressly provided
below):

 

(a)           Satisfaction
of Conditions.  Agent shall have
received evidence satisfactory to Agent that each of the conditions precedent
to a Permitted Acquisition set forth in Section 6.1(ii) – (xi)
of the Credit Agreement have been satisfied in connection with the BioStar
Stock Purchase (other than the conditions set forth in Sections 6.1(v),
which is hereby waived).

 

(b)           Guaranty
and Joinder.  Agent shall have
received a guaranty and joinder agreement, in form and substance satisfactory
to Agent, duly executed by BioStar pursuant to which, inter  alia,
BioStar joins the Credit Agreement and the other Loan Documents as a US Credit
Party and agrees to guaranty the Obligations of the Credit Parties under the
Loan Documents.

 

(c)           Security
Interest and Code Filings.

 

(i)            BioStar
shall have granted a valid first priority perfected (upon Agent filing the
documents referenced below that are required to be filed to perfect Agent’s
Lien) security interest (subject to Permitted Encumbrances) in all of its
assets to secure the Obligations of the Credit Parties and shall have executed or
authorized (as applicable) all documents (including financing statements under
the Code (or foreign equivalent) and other applicable documents under the laws
of any jurisdiction with respect to the perfection of Liens in form and
substance reasonably acceptable to Agent) as Agent may request in order to
perfect its security interest in such assets.

 

(ii)           BioStar
shall provide copies of Code (or the foreign equivalent thereof) search reports
listing all effective financing statements (or equivalent information) that
name BioStar as debtor, together with copies of such financing statements (or
equivalent information), none of which shall cover the assets of BioStar.

 

(iii)          Within
sixty (60) days of the BioStar Acquisition Effective Date or such longer period
as Agent shall consent to in its sole discretion, BioStar shall provide Control
Letters from (A) all issuers of uncertificated securities and financial
assets held by BioStar, (B) all securities intermediaries with respect to
all securities accounts and securities entitlements of BioStar, and (C) all
futures commission agents and clearing houses with respect to all commodities
contracts and commodities accounts held by BioStar.

 

(d)           Waivers.  Within sixty (60) days of the BioStar Acquisition
Effective Date or such longer period as Agent shall consent to in its sole
discretion, Agent, on behalf of Lenders, shall have received landlord waivers
and consents, bailee letters and mortgagee agreements, as applicable, in form
and substance reasonably satisfactory to Agent, in respect of BioStar.

 

(e)           Pledge
Amendment.  Agent shall have received
a pledge amendment to that certain Second Amended and Restated Pledge
Agreement, dated as of June 30, 2005, by and among Agent and the Credit
Parties listed on the signature pages thereto (as amended, restated,
supplemented or modified from time to time, the “Pledge Agreement”), in
form and substance satisfactory to Agent, duly executed by an authorized
officer of Innovations,

 

6

 

pursuant to which Innovations pledges one hundred
percent (100%) of the issued and outstanding Stock of BioStar (the “BioStar Stock”)
to Agent, together with all collateral and ancillary documentation required by
the Pledge Agreement, including, without limitation, original certificates
representing the BioStar Stock pledged by Innovations (with duly executed,
undated stock powers).

 

(f)            Cash
Management.  Within sixty (60) days
of the BioStar Acquisition Effective Date or such longer period as Agent shall
consent to in its sole discretion, Agent shall have received tri-party blocked
account agreements, in form and substance reasonably satisfactory to Agent,
duly executed and delivered by BioStar and each bank where BioStar has
established a deposit or disbursement account (other than payroll accounts), in
accordance with the requirements set forth in Section 1.8 and Annex
C of the Credit Agreement.

 

(g)           Schedules.  Agent shall have received updated Schedules
to the Credit Agreement, the Second Amended and Restated Security Agreement,
dated as of June 30, 2005, as amended from time to time, by and among Agent
that the Credit Parties listed on the signature page thereto, the Pledge
Agreement, the Second Amended and Restated US Intellectual Property Security
Agreement, dated as of June 30, 2005, as amended from time to time, by and
among Agent and the Credit Parties listed on the signature page thereto,
and such other Loan Documents as may be required in connection with the joinder
of BioStar, to reflect the joinder of BioStar to such agreements, in form and
substance satisfactory to Agent.

 

(h)           Organizational
Documents and Good Standing.  Agent
shall have received a copy of BioStar’s (i) organizational documents and
all amendments thereto and (ii) good standing certificates or the foreign
equivalent and certificates of qualification to conduct business in each jurisdiction
where its ownership or lease of property or the conduct of its business
requires such qualification, each dated a recent date and certified by the
applicable authorized Governmental Authority.

 

(i)            Bylaws
and Resolutions.  Agent shall have
received a copy of (i) BioStar’s bylaws (or foreign equivalent thereof)
and all amendments thereto, (ii) resolutions of BioStar’s board of
directors, if any, and, to the extent required under applicable law,
stockholders, approving and authorizing the BioStar Stock Purchase and the
execution, delivery and performance of the transaction documents to be executed
in connection with the BioStar Stock Purchase, and (iii) resolutions of BioStar’s
board of directors approving and authorizing the execution, delivery and
performance of the Loan Documents to which BioStar is, or will be a party and
the transactions to be consummated in connection therewith, each certified by
an authorized officer of BioStar as being in full force and effect without any
modification or amendment as of the BioStar Acquisition Effective Date.

 

(j)            Incumbency.  Agent shall have received a signature and
incumbency certificate of the officers of BioStar executing any Loan Document
or Joinder thereto, certified by an officer of BioStar as being true, accurate,
correct and complete in all respects.

 

(k)           BioStar
Stock Purchase Documents.  Agent
shall have received (i) an executed copy of the BioStar Stock Purchase
Agreement, together with all amendments

 

7

 

thereto, and all documentation delivered in connection
therewith (all of which shall be in form and substance reasonably satisfactory
to Agent), certified by an authorized officer of Innovations to be true and
complete and in full force and effect as of the Effective Date and (ii) a
certificate of an authorized officer of Innovations certifying as to the
matters set forth in Exhibit A hereto.

 

(l)            Opinion
of Counsel.  Agent shall have
received legal opinions of counsel acceptable to Agent, which shall provide
(subject to customary qualifications) that (i) the Loan Documents have
been duly authorized, executed and delivered by, and are enforceable against BioStar,
(ii) that the BioStar Stock Purchase was approved by all requisite
corporate action by Innovations, (iii) that the Amendment and the Amended
and Restated Notes (as defined below) have been duly authorized, executed and
delivered by, and are enforceable against the US Borrower, (iv) that the
Amended Credit Agreement (as defined below) is enforceable against the US
Borrower, (v) that the amendments contemplated by this Amendment are not
prohibited by the Indenture, the Subordinated Note Documents or the
Intercreditor Agreement, and (vi) such other opinions as Agent may
reasonably request, all in form and substance satisfactory to Agent.

 

(m)          Amended
and Restated Notes.  GE Capital and
ML Capital, as Lenders, shall have received amended and restated revolving
notes (the “Amended and Restated Notes”) reflecting the increased US
Revolving Loan Commitment.

 

(n)           Collateral
Assignment of BioStar Stock Purchase Documents.  Upon Agent’s request, Agent shall have
received a collateral assignment of the rights (but not the obligations) of
Innovations under the BioStar Stock Purchase Agreement and other documentation
executed in connection with the BioStar Stock Purchase.

 

(o)           Appointment
of Agent for Service of Process. 
Agent shall have received evidence that the Connecticut office of CT
Corporation has been appointed as agent for service of process for BioStar.

 

(p)           Amendment
of Pledge Agreements.  Within sixty
(60) days of the BioStar Acquisition Effective Date or such longer period as
Agent shall consent to in its sole discretion, Agent, on behalf of Lenders, shall
have received amendments to (i) that certain Quota Pledge and Perfection
of Pledge Regarding Two Quotas relating to the pledge of shares of Swissco,
among Inverness Medical International Holdings Corp., Inverness Medical
International Holdings Corp. II, and Agent, dated as of June 30, 2005
reflecting the increased US Revolving Loan Commitment; and (ii) that
certain Pledge of Shares relating to the pledge of shares of Orgenics
International Holdings BV between Innovations and Agent, dated as of June 30,
2005 reflecting the increased US Revolving Loan Commitment.

 

The
Borrowers and each of the other Credit Parties hereby acknowledge and agree
that the failure to satisfy any of the deliveries or conditions set forth above
in this Section 4 on or prior to the date required as set forth
above in connection with each such delivery or condition, as applicable, shall
constitute an immediate Event of Default under the Credit Agreement.

 

5.             IDT
Consent.  As of the Effective Date,
Agent and Requisite Lenders (a) consent to the IDT Stock Purchase in
accordance with the IDT Stock Purchase Agreement and

 

8

 

related documentation previously provided to and
approved by Agent (the “Draft IDT Stock Purchase Documents”), and (b) agree
that the IDT Stock Purchase on or before November 30, 2005, in accordance
with the Draft IDT Stock Purchase Documents, shall not constitute a breach of
the Credit Agreement or the other Loan Documents, provided, however,
that the Credit Parties do not expend any cash or other consideration in
connection with the IDT Stock Purchase other than (x) for costs and expenses
not to exceed €1,000,000 in the aggregate, (y) the IDT Closing Date
Consideration and (z) the Purchase Price Adjustment in an amount not to exceed €10,000,000.
 Agent and Requisite Lenders further
agree that, following the IDT Acquisition Effective Date, Inverness Iberica and
IDT Acquisition may change their respective names; provided  that
immediately following any such change, Borrowers shall provide Agent with a
full, complete and correct certificate of incorporation (or the foreign
equivalent thereof) of Inverness Iberica or IDT Acquisition, as applicable,
reflecting such change.

 

6.             Agreement
by Borrowers and Other Credit Parties Regarding IDT Stock Purchase.  The Borrowers and each of the other Credit
Parties hereby acknowledge and agree that, on or prior to the IDT Acquisition
Effective Date:

 

(a)           Satisfaction
of Conditions.  Agent shall have
received evidence satisfactory to Agent that each of the conditions precedent
to a Permitted Acquisition set forth in Section 6.1(ii) – (xi)
of the Credit Agreement have been satisfied in connection with the IDT Stock
Purchase (other than the conditions set forth in Sections 6.1(iv) (but
only to the extent such Indebtedness is otherwise permitted under the Credit
Agreement as amended hereby), (v), (vii) and (viii),
which are hereby waived).

 

(b)           Joinder.  Unless otherwise agreed to by Agent in its
sole discretion, prior to the later of (i) thirty (30) days after the
Effective Date and (ii) the IDT Acquisition Effective Date, Agent shall
have received a joinder agreement, in form and substance satisfactory to Agent,
duly executed by each of Inverness Iberica and IDT Acquisition pursuant to
which, inter  alia, each of Inverness Iberica and IDT Acquisition
join the Credit Agreement and the other Loan Documents as a Restricted Credit
Party.

 

(c)           Guaranty.  Unless otherwise agreed to by Agent in its
sole discretion, prior to the later of (i) thirty (30) days after the
Effective Date and (ii) the IDT Acquisition Effective Date, Agent shall
have received a guaranty, in form and substance satisfactory to Agent, duly
executed by Inverness Iberica and IDT Acquisition, pursuant to which each of
Inverness Iberica and IDT Acquisition guaranty the Obligations of the European
Credit Parties under the Loan Documents.

 

(d)           Security
Interest and Code Filings.  Unless
otherwise agreed to by Agent in its sole discretion, prior to the later of (i) thirty
(30) days after the Effective Date and (ii) the IDT Acquisition Effective
Date, Inverness Iberica and IDT Acquisition shall provide copies of Code (or
the foreign equivalent thereof) search reports listing all effective financing
statements (or equivalent information) that name Inverness Iberica or IDT
Acquisition, as applicable, as debtor, together with copies of such financing
statements (or equivalent information), none of which shall cover the assets of
Inverness Iberica or IDT Acquisition except to the extent permitted hereunder.

 

9

 

(e)           Pledge
Agreement.  Unless otherwise agreed
to by Agent in its sole discretion, prior to the later of (i) thirty (30)
days after the Effective Date and (ii) the IDT Acquisition Effective Date,
Agent shall have received (A) a pledge of one hundred percent (100%) of
the issued and outstanding Stock of IDT Acquisition (the “IDT Acquisition Stock”)
pursuant to a pledge agreement to be entered into between Swissco and Agent,
together with, to the extent such Stock is certificated, original certificates
representing the IDT Acquisition Stock pledged by Swissco (with duly executed, undated
stock powers), and (B) a pledge of one hundred percent (100%) of the
issued and outstanding Stock of Inverness Iberica (the “Inverness Iberica
Stock”) pursuant to a pledge agreement to be entered into between IDT Acquisition
and Agent, together with, to the extent such Stock is certificated,  original certificates representing the Inverness
Iberica Stock pledged by IDT Acquisition (with duly executed, undated stock
powers).

 

(f)            Schedules.  Unless otherwise agreed to by Agent in its
sole discretion, prior to the later of (i) thirty (30) days after the
Effective Date and (ii) the IDT Acquisition Effective Date, Agent shall
have received updated Schedules to the Credit Agreement and such other Loan
Documents as may be required in connection with the joinder of Inverness
Iberica and IDT Acquisition, to reflect the joinder of Inverness Iberica and
IDT Acquisition to such agreements, in form and substance satisfactory to
Agent.

 

(g)           Organizational
Documents and Good Standing.  Unless
otherwise agreed to by Agent in its sole discretion, prior to the later of (i) thirty
(30) days after the Effective Date and (ii) the IDT Acquisition Effective
Date, Agent shall have received a copy of each of Inverness Iberica’s and IDT
Acquisition’s (A) organizational documents and all amendments thereto and (B) good
standing certificates or the foreign equivalent and certificates of
qualification to conduct business in each jurisdiction where its ownership or
lease of property or the conduct of its business requires such qualification,
each dated a recent date and certified by the applicable authorized
Governmental Authority.

 

(h)           Bylaws
and Resolutions.  Unless otherwise
agreed to by Agent in its sole discretion, prior to the later of (i) thirty
(30) days after the Effective Date and (ii) the IDT Acquisition Effective
Date, Agent shall have received a copy of (A) each of Inverness Iberica’s
and IDT Acquisition’s bylaws (or foreign equivalent thereof) and all amendments
thereto, (B) resolutions of each of Inverness Iberica’s and IDT
Acquisition’s board of directors and, to the extent required under applicable
law, stockholders, approving and authorizing the IDT Stock Purchase and the
execution, delivery and performance of the transaction documents to be executed
in connection with the IDT Stock Purchase, and (C) resolutions of each of Inverness
Iberica’s and IDT Acquisition’s board of directors approving and authorizing
the execution, delivery and performance of the Loan Documents to which Inverness
Iberica and IDT Acquisition is, or will be a party and the transactions to be
consummated in connection therewith, each certified by an authorized officer of
each of Inverness Iberica and IDT Acquisition (after giving effect to the IDT
Stock Purchase) as being in full force and effect without any modification or
amendment as of the IDT Acquisition Effective Date.

 

(i)            Incumbency.  Unless otherwise agreed to by Agent in its
sole discretion, prior to the later of (i) thirty (30) days after the
Effective Date and (ii) the IDT Acquisition Effective Date, Agent shall
have received a signature and incumbency certificate of

 

10

 

the officers of each of Inverness Iberica and IDT
Acquisition executing any Loan Document or Joinder thereto, certified by an
officer of Inverness Iberica and IDT Acquisition as being true, accurate,
correct and complete in all respects.

 

(j)            IDT
Stock Purchase Documents.  Agent
shall have received (i) an executed copy of the IDT Stock Purchase
Agreement, together with all amendments thereto, and all documentation
delivered in connection therewith (all of which shall be in form and substance
reasonably satisfactory to Agent), certified by an authorized officer of IDT Acquisition
to be true and complete and in full force and effect as of the Effective Date
and (ii) a certificate of an authorized officer of IDT Acquisition certifying
as to the applicable matters set forth in Exhibit A hereto.

 

(k)           Opinion
of Counsel.  Unless otherwise agreed
to by Agent in its sole discretion, prior to the later of (i) thirty (30)
days after the Effective Date and (ii) the IDT Acquisition Effective Date,
Agent shall have received legal opinions of counsel acceptable to Agent, which
shall provide (subject to customary qualifications) that (i) the Loan
Documents have been duly authorized, executed and delivered by, and are
enforceable against each of Inverness Iberica and IDT Acquisition (and in the
case of the pledge of Stock of IDT Acquisition, Swissco), (ii) that the IDT
Stock Purchase was approved by all requisite corporate action by Inverness
Iberica and IDT Acquisition and (iii) such other opinions as Agent may
reasonably request, all in form and substance satisfactory to Agent.

 

(l)            Collateral
Assignment of IDT Stock Purchase Documents. 
Upon Agent’s request, Agent shall have received a collateral assignment
of the rights (but not the obligations) of Swissco under the IDT Stock Purchase
Agreement and other documentation executed in connection with the IDT Stock
Purchase.

 

(m)          Appointment
of Agent for Service of Process. 
Agent shall have received evidence that the Connecticut office of CT
Corporation has been appointed as agent for service of process for Inverness
Iberica and IDT Acquisition.

 

The
Borrowers and each of the other Credit Parties hereby acknowledge and agree
that the failure to satisfy any of the deliveries or conditions set forth above
in this Section 6 on or prior to the date required as set forth
above in connection with each such delivery or condition, as applicable, shall
constitute an immediate Event of Default under the Credit Agreement.

 

7.             Covenant.  The Credit Parties shall not amend the Draft BioStar
Stock Purchase Documents, the executed BioStar Stock Purchase Agreement, the
Draft IDT Stock Purchase Documents or the executed IDT Stock Purchase Agreement
in each case in a manner which adversely affects the Lenders without the prior
written consent of Agent.  Any failure of
the Credit Parties to comply with this covenant (a) with respect to the
Draft BioStar Stock Purchase Documents or the Draft IDT Stock Purchase Documents
shall result in this Amendment becoming immediately null and void and of no
further force and effect and (b) with respect to the BioStar Stock
Purchase Agreement or the IDT Stock Purchase Agreement shall constitute an
immediate Event of Default under the Credit Agreement.

 

11

 

8.             Representations
and Warranties.  To induce Agent and
Requisite Lenders to enter into this Amendment, the Credit Parties hereby, jointly
and severally, represent and warrant that:

 

(a)           The
execution, delivery and performance by each Credit Party of this Amendment and
the performance of the Credit Agreement, as amended by this Amendment (the “Amended
Credit Agreement”): (i) are within such Person’s corporate, company or
partnership power; (ii) have been (or will be prior to execution thereof)
duly authorized by all necessary corporate, limited liability company or
limited partnership action; (iii) do not contravene any provision of such Person’s
charter, bylaws or equivalent constitutive documents or partnership or
operating agreement, as applicable; (iv) do not violate any law or
regulation, or any order or decree of any court or Governmental Authority; (v) do
not conflict with or result in the breach or termination of, constitute a
default under or accelerate or permit the acceleration of any performance
required by, any indenture, mortgage, deed of trust, lease, agreement or other
instrument to which such Person is a party or by which such Person or any of
its property is bound; (vi) do not result in the creation or imposition of
any Lien upon any of the property of such Person, other than a Lien in favor of
Agent; and (vii) do not require the consent or approval of any
Governmental Authority or any other Person except those which will have been
duly obtained, made or complied with prior to the Effective Date.

 

(b)           This
Amendment has been duly executed and delivered by or on behalf of each of the
Credit Parties.

 

(c)           This
Amendment and the Amended Credit Agreement constitutes a legal, valid and
binding obligation of each of the Credit Parties, enforceable against each of
them in accordance with its terms, except as enforcement may be limited by
bankruptcy, insolvency, fraudulent conveyance or transfer or other laws
affecting creditors’ rights generally or by equitable principals of general
applicability.

 

(d)           No
Default or Event of Default has occurred and is continuing or would result
after giving effect to the provisions of this Amendment.

 

(e)           No
action, claim or proceeding is now pending or, to the knowledge of any Credit
Party, threatened against such Credit Party, at law, in equity or otherwise,
before any court, board, commission, agency or instrumentality of any foreign,
federal, state, or local government or of any agency or subdivision thereof, or
before any arbitrator or panel of arbitrators, which (i) challenges any
Credit Party’s right or power to enter into or perform any of its obligations
under this Amendment or any other Loan Document to which it is or will be, a
party, or the validity or enforceability of this Amendment, the Amended Credit
Agreement or any Loan Document or any action taken thereunder, or (ii) has
a reasonable risk of being determined adversely to any Credit Party and that,
if so determined, could reasonably be expected to have a Material Adverse
Effect after giving effect to this Amendment.

 

(f)            The
representations and warranties of the Credit Parties contained in the Amended Credit
Agreement and each other Loan Document shall, after giving effect hereto, be
true and correct on and as of (i) the date hereof, and (ii) the
Effective Date, in each case, with the same effect as if such representations
and warranties had been made on and as of

 

12

 

such date, except that any such representation or
warranty which is expressly made only as of a specified date need be true only
as of such date.

 

9.             No
Amendments/Waivers/Consents.  Except
as expressly provided herein (a) the Credit Agreement and the other Loan
Documents shall be unmodified and shall continue to be in full force and effect
in accordance with their terms, (b) the consents and agreements of the
Agent and Requisite Lenders set forth herein shall be limited strictly as
written and shall not constitute a consent or agreement to any transaction not
specifically described in connection with any such consent and/or agreement,
and (c) this Amendment shall not be deemed a waiver of any term or
condition of any Loan Document and shall not be deemed to prejudice any right
or rights which Agent or any Lender may now have or may have in the future
under or in connection with any Loan Document or any of the instruments or
agreements referred to therein, as the same may be amended from time to time.

 

10.           Affirmation
of Obligations.  Each of the Credit
Parties hereby acknowledges, agrees and affirms (a) its obligations under
the Credit Agreement and the other Loan Documents, including, without
limitation, its guaranty obligations thereunder, (b) that such guaranty
shall apply to the Obligations in accordance with the terms thereof, (c) the
grant of the security interest in all of its assets pursuant to the Loan
Documents and (d) that such liens and security interests created and granted
are valid and continuing and secure the Obligations in accordance with the
terms thereof.

 

11.           Outstanding
Indebtedness; Waiver of Claims.  Each
of Borrowers and the other Credit Parties hereby acknowledges and agrees that
as of September 28, 2005, (a) the outstanding balance of the European
Revolving Loan is $5,000,000, (b) the outstanding balance of the US
Revolving Loan is $16,000,000, (c) the outstanding balance of the US Term
Loan is $0, and (d) the outstanding balance of European Term Loan is $0.  Borrowers and each other Credit Party hereby
waive, release, remise and forever discharge Agent, Lenders and each other
Indemnified Person from any and all claims, suits, actions, investigations,
proceedings or demands arising out of or in connection with the Credit
Agreement (collectively, “Claims”), whether based in contract, tort,
implied or express warranty, strict liability, criminal or civil statute or
common law of any kind or character, known or unknown, which any Borrower or
any other Credit Party ever had, now has or might hereafter have against Agent
or Lenders which relates, directly or indirectly, to any acts or omissions of
Agent, Lenders or any other Indemnified Person on or prior to the Effective
Date, provided, that no Borrower nor any other Credit Party waives any
Claim solely to the extent such Claim relates to Agent’s or any Lender’s gross
negligence or willful misconduct.

 

12.           Fees
and Expenses.

 

(a)           Increased Line
Fee.  To induce GE Capital and ML
Capital to increase their respective US Revolving Loan Commitments, Borrowers
hereby agree to pay Agent, for the ratable benefit of GE Capital and ML Capital,
as Lenders, an increased line fee in the amount of $200,000 in immediately
available funds, payable on the BioStar Acquisition Effective Date (the “Increased
Line Fee”).

 

13

 

(b)           Expenses.  Borrowers hereby reconfirm their obligations
pursuant to Section 11.3 of the Credit Agreement to pay and
reimburse Agent for all reasonable costs and expenses (including, without
limitation, reasonable fees of counsel) incurred in connection with the
negotiation, preparation, execution and delivery of this Amendment and all
other documents and instruments delivered in connection herewith..

 

13.           Effectiveness.  Effectiveness.  Upon satisfaction in full in the judgment of
Agent of each of the following conditions, this Amendment shall be deemed
effective as of September 30, 2005 (the “Effective Date”):

 

(a)           Amendment.  Agent shall have received four (4) original
signature pages to this Amendment, duly executed and delivered by Agent, Requisite
Lenders, and each of the Credit Parties.

 

(b)           Payment
of Fees and Expenses.  Borrowers
shall have paid to Agent all costs, fees and expenses owing in connection with this
Amendment and the other Loan Documents and due to Agent (including, without
limitation, the Increased Line Fee and reasonable legal fees and expenses).

 

(c)           Representations
and Warranties.  The representations
and warranties of or on behalf of each of the Credit Parties in this Amendment
shall be true and correct on and as of the date hereof and the Effective Date.

 

14.           GOVERNING
LAW.  THIS AMENDMENT SHALL BE
GOVERNED BY, AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW
YORK.

 

15.           Counterparts.  This Amendment may be executed by the parties
hereto on any number of separate counterparts and all of said counterparts
taken together shall be deemed to constitute one and the same instrument.

 

14

 

IN WITNESS
WHEREOF, this Amendment has been duly executed as of the date first written
above.

 

	
   

  	
  BORROWERS

  
	
   

  	
   

  
	
   

  	
  WAMPOLE
  LABORATORIES, LLC

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
  /s/ Duane L. James

  
	
   

  	
  Name:

  	
  Duane L. James

  
	
   

  	
  Title:

  	
  Treasurer

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  INVERNESS
  MEDICAL (UK) HOLDINGS LIMITED

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ David Scott

  
	
   

  	
  Name:

  	
   

  
	
   

  	
  Title:

  	
   

  
					

 

 

	
   

  	
  AGENT AND LENDERS

  
	
   

  	
   

  
	
   

  	
  GENERAL ELECTRIC CAPITAL

  
	
   

  	
  CORPORATION, as Agent and Lender

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Steven Wagnblas

  
	
   

  	
   

  	
  Duly Authorized Signatory

  
	
   

  	
   

  
	
   

  	
  MERRILL LYNCH CAPITAL, a division of

  Merrill Lynch Business Financial Services Inc.,

  as a Lender

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Faraaz Kamran

  
	
   

  	
   

  	
  Duly Authorized Signatory

  
	
   

  	
   

  
	
   

  	
  UBS AG, CAYMAN ISLANDS BRANCH, as a

  Lender

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Wilfred V. Saint

  
	
   

  	
   

  	
  Duly Authorized Signatory

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Sailoz Sikka

  
	
   

  	
   

  	
  Duly Authorized Signatory

  

 

I-16

 

The following Persons are signatories to this
Amendment in their capacity as Credit Parties and not as Borrowers.

 

	
   

  	
  APPLIED BIOTECH, INC.

  
	
   

  	
  ADVANTAGE DIAGNOSTICS CORPORATION

  
	
   

  	
  FOREFRONT DIAGNOSTICS, INC.

  
	
   

  	
  INVERNESS MEDICAL INTERNATIONAL

  
	
   

  	
  HOLDING CORP.

  
	
   

  	
  INVERNESS MEDICAL INTERNATIONAL

  
	
   

  	
  HOLDING CORP. II

  
	
   

  	
  INVERNESS MEDICAL, INC.

  
	
   

  	
  INNOVATIONS RESEARCH, LLC

  
	
   

  	
  ISCHEMIA TECHNOLOGIES, INC.

  
	
   

  	
  IVC INDUSTRIES, INC.

  
	
   

  	
  MORPHEUS ACQUISITION CORP.

  
	
   

  	
  OSTEX INTERNATIONAL, INC.

  
	
   

  	
  SELFCARE TECHNOLOGY, INC.

  
	
   

  	
  UNIPATH ONLINE, INC.

  
	
   

  	
  BINAX, INC.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
  /s/ Duane L. James

  
	
   

  	
  Name:

  	
  Duane L. James

  
	
   

  	
  Title:

  	
  Treasurer, Treasurer, Treasurer, Treasurer,

  
	
   

  	
   

  	
  Treasurer, Treasurer, Treasurer, Treasurer,

  
	
   

  	
   

  	
  Treasurer, Treasurer, Treasurer, Treasurer,

  
	
   

  	
   

  	
  Treasurer, Vice President, respectively

  

 

 

	
   

  	
  CAMBRIDGE DIAGNOSTICS IRELAND LIMITED

  
	
   

  	
  DMD,
  DIENSTLEISTUNGEN & VERTRIEB FÜR MEDIZIN UND DIAGNOSTIK GMBH

  
	
   

  	
  INVERNESS MEDICAL CANADA, INC.

  
	
   

  	
  INVERNESS MEDICAL EURASIA LIMITED

  
	
   

  	
  INVERNESS MEDICAL FRANCE SAS

  	
   

  
	
   

  	
  INVERNESS MEDICAL GERMANY GMBH

  
	
   

  	
  ORGENICS INTERNATIONAL HOLDINGS BV

  
	
   

  	
  SCANDINAVIAN MICRO BIODEVICES APS

  
	
   

  	
  STIRLING MEDICAL INNOVATIONS LIMITED INVERNESS
  MEDICAL SWITZERLAND GMBH

  
	
   

  	
  UNIPATH DIAGNOSTICS GMBH

  
	
   

  	
  VIVA DIAGNOSTIKA -
  DIAGNOSTISCHE PRODUKTE GMBH

  
	
   

  	
  INVERNESS MEDICAL JAPAN, LTD.

  
	
   

  	
  INVERNESS MEDICAL INNOVATIONS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
  /s/ Duane L. James

  
	
   

  	
  Name:

  	
  Duane L. James

  
	
   

  	
  Title:

  	
  Authorized Person, Authorized Person,

  
	
   

  	
   

  	
  Authorized Person, Authorized Person,

  
	
   

  	
   

  	
  Authorized Person, Authorized Person,

  
	
   

  	
   

  	
  Authorized Person, Authorized Person,

  
	
   

  	
   

  	
  Authorized Person, Authorized Person,

  
	
   

  	
   

  	
  Authorized Person, Authorized Person,

  
	
   

  	
   

  	
  Authorized Person, Authorized Person,

  
	
   

  	
   

  	
  Treasurer, respectively

  
	
   

  	
   

  	
   

  
	
   

  	
  INVERNESS MEDICAL INVESTMENTS, LLC

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
  /s/ Jay McNamara

  
	
   

  	
  Name:

  	
  Jay McNamara

  
	
   

  	
  Title:

  	
  Assistant
  Secretary

  
	
   

  	
   

  	
   

  
	
   

  	
  INVERNESS MEDICAL CANADA, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
  /s/ Doug Shaffer

  
	
   

  	
  Name:

  	
  Doug Shaffer

  
	
   

  	
  Title: President

  
	
   

  	
   

  	
   

  
	
   

  	
  UNIPATH LIMITED

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  	
  /s/ David Scott

  
	
   

  	
  Name:

  	
  David Scott

  
	
   

  	
  Title: Chairman

  
					

 

I-18

 

ANNEX I (FROM ANNEX A
– COMMITMENTS DEFINITION)
TO

CREDIT AGREEMENT

 

Commitments as of
the BioStar Acquisition Effective Date:

 

 

	
  GENERAL
  ELECTRIC CAPITAL CORPORATION:

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  US Revolving
  Loan Commitment

  	
   

  	
   

  	
   

  
	
  (including a US
  Swing Line Commitment of $5,000,000):

  	
   

  	
  $

  	
  27,500,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  European
  Revolving Loan Commitment

  	
   

  	
   

  	
   

  
	
  (including a
  European Swing Line Commitment of $5,000,000):

  	
   

  	
  $

  	
  17,500,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  US Term Loan Commitment:

  	
   

  	
  $

  	
  0

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  European Term
  Loan Commitment:

  	
   

  	
  $

  	
  0

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  MERRILL
  LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc.

  	
   

  	
   

  	
   

  
	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  US Revolving Loan Commitment:

  	
   

  	
  $

  	
  25,000,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  European Revolving Loan Commitment:

  	
   

  	
  $

  	
  15,000,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  US Term Loan Commitment:

  	
   

  	
  $

  	
  0

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  European Term Loan Commitment: :

  	
   

  	
  $

  	
  0

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  UBS AG, CAYMAN ISLANDS BRANCH

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  US Revolving Loan Commitment:

  	
   

  	
  $

  	
  7,500,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  European Revolving Loan Commitment:

  	
   

  	
  $

  	
  7,500,000

  	
   

  

 

I-1

 

Exhibit A

 

No Credit Party and, to the Credit Parties’ knowledge, no other Person
party thereto is in default in the performance or compliance with any
provisions of the [IDT Stock Purchase Agreement/BioStar Stock Purchase
Agreement].  The [IDT Stock Purchase
Agreement/BioStar Stock Purchase Agreement] complies with, and the [IDT Stock
Purchase/BioStar Stock Purchase] has been consummated in accordance with, all
applicable laws.  The [IDT Stock Purchase
Agreement/BioStar Stock Purchase Agreement] is in full force and effect as of
the date hereof and has not been terminated, rescinded or withdrawn.  All requisite approvals by Governmental
Authorities having jurisdiction over any Credit Party and other Persons
referenced therein with respect to the consummation of the [IDT Stock
Purchase/BioStar Stock Purchase] have been obtained, and no such approvals
impose any conditions to the consummation of the [IDT Stock Purchase/BioStar
Stock Purchase] or, other than as described in the [IDT Stock Purchase
Agreement/BioStar Stock Purchase Agreement], to the conduct by any Credit Party
of its business thereafter.  To the best
of each Credit Party’s knowledge, none of the [Innogenetics NV’s/Thermo
BioAnalysis Corporation’s] representations or warranties in the [IDT Stock
Purchase Agreement/BioStar Stock Purchase Agreement] contain any untrue
statement of a material fact or omit any fact necessary to make the statements
therein not misleading.  Each of the
representations and warranties given by each applicable Credit Party in the [IDT
Stock Purchase Agreement/BioStar Stock Purchase Agreement] is true and correct
in all material respects, and, notwithstanding anything contained in the [IDT
Stock Purchase Agreement/BioStar Stock Purchase Agreement] to the contrary,
such representations and warranties of the Credit Parties are incorporated into
the Credit Agreement by delivery of this certificate and shall, solely for
purposes of the Credit Agreement and the benefit of Agent and Lenders, survive
the consummation of the [IDT Stock Purchase/BioStar Stock Purchase]; provided
that a breach by any of the Credit Parties of any such representations and
warranties so incorporated and as to which a similar representation and
warranty is not independently made in the Credit Agreement shall not constitute
a breach of the Credit Agreement unless such breach causes any such
representation and warranty to be materially inaccurate.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]